SRD 174Alternative Names: SRD-174
Latest Information Update: 22 Jul 2015
At a glance
- Originator Serentis
- Class Antipruritics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pruritus
Most Recent Events
- 22 Jul 2015 Discontinued - Phase-II for Pruritus in USA prior to July 2015 (Topical)
- 01 Jan 2009 Phase-II clinical trials in Pruritus in USA (Topical)